DDrare: Database of Drug Development for Rare Diseases

302. レーベル遺伝性視神経症
［臨床試験数：20，薬物数：14（DrugBank：4），標的遺伝子数：5，標的パスウェイ数：32］

Searched query = "Leber hereditary optic neuropathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Béfizal; Cyclosporine; GS010; Genetic: GS010; Idebenone; Lenadogene nolparvovec; NADH; PENDING; Pending; RAAV2-ND4; RAAV2/2-ND4 VECTOR; Recombinant AAV vector serotype 2 containing the human wild type mitochondrial ND4 gene; Recombinant Adeno-Associated Viral vector, serotype 2 (rAAV2/2) containing the human wild-type mitochondrial NADH Dehydrogenase 4 gene (ND4); VA

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04561466 (ClinicalTrials.gov)	March 26, 2019	14/3/2019	Trial of Befizal® 200 mg for the Treatment of Leber Hereditary Optic Neuropathy	Study of Efficacy of Befizal® 200 mg for the Treatment of Leber Hereditary Optic Neuropathy	Safety Issues;Efficacy, Self	Drug: Béfizal	Hôpital Necker-Enfants Malades	European Georges Pompidou Hospital;CLAIROP	Recruiting	18 Years	N/A	All	14	Phase 2;Phase 3	France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04561466
(ClinicalTrials.gov)

March 26, 2019

14/3/2019

Trial of Befizal® 200 mg for the Treatment of Leber Hereditary Optic Neuropathy

Study of Efficacy of Befizal® 200 mg for the Treatment of Leber Hereditary Optic Neuropathy

Safety Issues;Efficacy, Self

Drug: Béfizal

Hôpital Necker-Enfants Malades

European Georges Pompidou Hospital;CLAIROP

Recruiting

18 Years

N/A

All

Phase 2;Phase 3

France